Generic utilization and cost-sharing for prescription drugs.

Teresa Bernard Gibson, Catherine G McLaughlin, Dean G Smith
{"title":"Generic utilization and cost-sharing for prescription drugs.","authors":"Teresa Bernard Gibson,&nbsp;Catherine G McLaughlin,&nbsp;Dean G Smith","doi":"10.1108/s0731-2199(2010)0000022012","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study is to estimate the own- and cross-price elasticity of brand-name outpatient prescription drug cost-sharing for maintenance medications and to estimate the effects of changes in the price differential between generic and brand-name prescription drugs.</p><p><strong>Methodology/approach: </strong>We first review the literature on the effects of an increase in brand-name drug patient cost-sharing. In addition, we analyze two examples of utilization patterns in filling behavior associated with an increase in brand-name cost-sharing for patients in employer-sponsored health plans with chronic illness.</p><p><strong>Findings: </strong>We found that the own-price elasticity of demand for brand-name prescription drugs was inelastic. However, the cross-price elasticity was not consistent in sign, and utilization patterns for generic prescription fills did not always increase after a rise in brand-name cost-sharing.</p><p><strong>Research limitations: </strong>The empirical examples are limited to the experience of patients with employer-sponsored health insurance.</p><p><strong>Practical implications: </strong>The common practice of increasing brand-name prescription drug patient cost-sharing to increase consumption of generic drugs may not always result in higher generic medication use. Higher brand-name drug cost-sharing levels may result in discontinuation of chronic therapies, instead of therapeutic switching.</p><p><strong>Originality/value of chapter: </strong>The value of this chapter is its singular focus on the effects of higher brand-name drug cost-sharing through a synthesis of the literature examining the own- and cross-price elasticity of demand for brand-name medications and two empirical examples of the effects of changes in brand-name cost-sharing.</p>","PeriodicalId":79553,"journal":{"name":"Advances in health economics and health services research","volume":"22 ","pages":"195-219"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1108/s0731-2199(2010)0000022012","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in health economics and health services research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1108/s0731-2199(2010)0000022012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

Purpose: The purpose of this study is to estimate the own- and cross-price elasticity of brand-name outpatient prescription drug cost-sharing for maintenance medications and to estimate the effects of changes in the price differential between generic and brand-name prescription drugs.

Methodology/approach: We first review the literature on the effects of an increase in brand-name drug patient cost-sharing. In addition, we analyze two examples of utilization patterns in filling behavior associated with an increase in brand-name cost-sharing for patients in employer-sponsored health plans with chronic illness.

Findings: We found that the own-price elasticity of demand for brand-name prescription drugs was inelastic. However, the cross-price elasticity was not consistent in sign, and utilization patterns for generic prescription fills did not always increase after a rise in brand-name cost-sharing.

Research limitations: The empirical examples are limited to the experience of patients with employer-sponsored health insurance.

Practical implications: The common practice of increasing brand-name prescription drug patient cost-sharing to increase consumption of generic drugs may not always result in higher generic medication use. Higher brand-name drug cost-sharing levels may result in discontinuation of chronic therapies, instead of therapeutic switching.

Originality/value of chapter: The value of this chapter is its singular focus on the effects of higher brand-name drug cost-sharing through a synthesis of the literature examining the own- and cross-price elasticity of demand for brand-name medications and two empirical examples of the effects of changes in brand-name cost-sharing.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
处方药的仿制药利用和费用分担。
目的:本研究的目的是评估品牌门诊处方药维持药物成本分担的自身价格弹性和交叉价格弹性,并评估仿制药和品牌药价格差异变化的影响。方法/方法:我们首先回顾了关于品牌药患者成本分担增加的影响的文献。此外,我们分析了两个使用模式的填充行为的例子,这些行为与雇主赞助的慢性疾病健康计划中品牌费用分担的增加有关。研究发现:我国名牌处方药需求的自身价格弹性不具有弹性。然而,交叉价格弹性在符号上并不一致,仿制药的使用模式并不总是随着品牌成本分担的增加而增加。研究局限:实证例子仅限于雇主赞助的健康保险患者的经验。实际意义:增加品牌处方药患者费用分担以增加仿制药消费的常见做法可能并不总是导致更高的仿制药使用。较高的品牌药费用分担水平可能导致慢性治疗的中断,而不是治疗转换。本章的原创性/价值:本章的价值在于它通过综合研究品牌药物需求的自身价格弹性和交叉价格弹性的文献,以及两个品牌成本分担变化影响的实证例子,专注于更高的品牌药物成本分担的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Effect of Education on Health Behavior after Screening for Colorectal Cancer Educational Heterogeneity in the Association between Smoking Cessation and Health Information Birth Spacing and Educational Outcomes Unemployment Insurance and Physical Activity Causal Effects of Maternal Schooling on Child Immunization in India
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1